Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID-19 Related Outcomes Among Cancer Patients Treated With TKIs, Including RegorafeNib or SorAfenib

NCT05594147 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05594147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05594147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID-19 Related Outcomes Among Cancer Patients Treated With TKIs, Including RegorafeNib or SorAfenib
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
October 31, 2022
Completion date
April 21, 2023
Enrollment
4,103 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019 (covid-19), malignant solid tumors, sars-cov-2 infection